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ABSTRACT 
 
OBJECTIVE: In 2011, the World Health Organization reported 8.7 million new cases of 
tuberculosis and 1.4 million tuberculosis-related deaths worldwide. The causative agent of this 
disease Mycobacterium tuberculosis is a notoriously persistent pathogen whose treatment 
requires a 6-9 month course of multiple antibiotics to clear the infection. Here, we used next 
generation DNA sequencing to identify several genetic factors involved in the tolerance of M. 
tuberculosis to the antibiotic rifampicin in the context of the biofilm, a common bacterial stress 
survival strategy. 
METHODS: A transposon insertion mutant library was constructed in the Erdman strain of M. 
tuberculosis. The library was then grown planktonically or in a biofilm and exposed to 5µg/ml of 
rifampicin. After exposure samples were processed and plated for colony formation. DNA was 
extracted from the colonies and prepared for sequencing by PCR amplification of transposon 
junction sites.  DNA of these sites was sequenced using Illumina Hi-Seq technology and 
analyzed to find differential representation of transposon mutants between the unexposed and 
exposed library samples. 
RESULTS: Biofilms of M. tuberculosis are more tolerant than planktonic samples in vitro to 
rifampicin treatment. Seven genes at eight genomic positions were found to contain insertion 
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sites that were ubiquitous in the samples unexposed to rifampicin, but found to be greatly 
decreased in the exposed biofilm samples: Rv0385, Rv1508c (at two positions), Rv1819c, 
Rv2779c, Rv3164c, Rv3796 and Rv3868. 
DISCUSSION: Further analysis of these mutants by using knockouts and studying the effects in 
vitro or in a mouse model will be necessary to confirm their role in rifampicin tolerance in an 
actual infection and determine any possible clinical benefits in exploiting these genetic factors. 
As latent infection remains a significant problem in global public health, exploitation of targets 
that contribute the persistence of infection could be a valuable tool in clearing infections. 
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1.0  INTRODUCTION 
1.1 GLOBAL DISEASE BURDEN OF TUBERCULOSIS 
Tuberculosis (TB) in humans is caused by infection with the bacterium Mycobacterium 
tuberculosis (MTB). According to the most recently available data by the World Health 
Organization, there were 8.7 million newly reported cases of TB and 1.4 million TB-related 
deaths in 2011 [1]. The global burden of disease remains at an alarmingly high level; TB is the 
leading cause of death by infectious disease worldwide, and it has been estimated that one third 
of the world’s total population has been infected.  Multidrug-resistant tuberculosis (MDR-TB), 
defined as being resistant to the frontline antibiotics isoniazid and rifampicin, represents roughly 
five percent of active TB cases. There were approximately 60,000 new cases of MDR-TB 
reported in 2011, a number which has increased steadily over the past eight years.  Eighty-four 
countries have also now reported at least one case of extensively drug-resistant tuberculosis 
(XDR-TB), defined as being resistant to both isoniazid and rifampicin as well as 
fluoroquinolones and at least one injectable second line antibiotic [2].  Human 
Immunodeficiency Virus (HIV) and TB co-infection also remains a substantial public health 
concern, especially in Africa where 80% of the total HIV-tuberculosis co-infections were 
reported. Approximately 400,000 of the 1.4 million TB-related deaths reported in 2011 involved 
co-infections with HIV [1]. Geographically, TB persists as a major public health threat 
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throughout much of the developing world including South Asia, Sub-Saharan Africa and parts of 
the Middle East, South America and Russia [3]. 
1.2 MTB: A PERSISTENT PATHOGEN 
Although it is estimated that one third of the global population has been infected by MTB, only 
5-10% of tuberculosis-infected individuals develop clinical disease symptoms. How these 
bacteria remain latent in the host is an important question in the study of the disease. Once an 
individual is infected with the bacterium, macrophages in the lung engulf the bacteria by 
phagocytosis, but bacterial immune evasion factors prevent the phagosome from fusing with the 
lysosome that can lyse the bacteria [4].  The pathogen cannot be cleared by either the innate 
immune response or the T-cell adaptive immune response that is instigated by dendritic cells 
after infection [5]. Usually this adaptive response is triggered by 4-6 weeks into the infection. In 
many cases, this is still not enough to clear the bacteria, and instead the bacteria become 
sequestered in the lung inside aggregates of host cells called granulomas. Granuloma 
architectures are typically comprised of an acellular center surrounded by large multi-nucleated 
macrophages, called Langhans giant cells, which are further surrounded by an outer ring of T-
leukocytes [6]. Long-term persistence of MTB in this hostile environment of immunocompetent 
granluomas is considered an underlying factor in the development of asymptomatic infection.   
Clearance of MTB takes 6-9 months of directly observed therapy-short course (DOTS), 
which is comprised of antibiotic treatment with rifampicin, isoniazid and usually ethambutol 
under the direct observation of a community healthcare worker. This multi-drug intervention was 
developed nearly forty years ago, and its usefulness is increasingly being challenged by the 
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development of MDR-TB. This is especially true in resource-limited regions where MDR-TB is 
a common result of incomplete treatment [7, 8]. Latent infections of MTB and the aggressive and 
lengthy treatment remains a major obstacle in treating this wicked problem in global health. 
1.3 MYCOBACTERIA READILY FORM MULTICELLULAR STRUCTURES 
Mycobacteria, when grown in vitro will readily form a pellicle at the air-liquid interface of the 
growth media. In fact, historically this has posed challenges in culturing strains of mycobacterial 
species in vitro. Since the 1950’s, the solution to this problem has been to use Tween-80, a 
surfactant and emulsifier, to obtain a homogenous suspension of bacteria in culture without 
affecting virulence [9].  However when grown in this condition, certain biological characteristics 
of the bacteria are altered. Being neither truly Gram-positive nor Gram-negative, mycobacteria 
are unique for their waxy, impermeable and lipid-rich cell wall. When grown in the presence of 
detergent, the cellular lipids on the outer wall are altered to be more permeable to small 
molecules, including antibiotics [10]. Furthermore, bacteria grown in a homogenous suspension 
experience homogenous access to nutrients. In the macroscopic structures that these bacteria 
would form normally, a gradient of nutrient and oxygen access would create a subpopulation of 
cells at the core of the structure experiencing greater stress than cells dispersing off of the 
structures’ outer edges. It has been shown that M. tuberculosis expresses a unique genetic profile 
under starvation conditions, and it is logical that the differing stress levels would produce 
phenotypically unique subpopulations that have adapted to tolerate the harsher conditions at the 
core of such structures [11]. The phenotypic diversity and biological adaptations that result from 
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the accumulation of bacteria in multicellular structures remains largely overlooked in the study 
of persistence of pathogenic mycobacteria. 
1.4 BIOFILMS AS A DISTINCT BACTERIAL LIFESTYLE 
Bill Costerton coined the term “biofilm” in 1978 to describe an aggregate of bacterial cells 
attached to a substratum [12]. Later, his group described microcolonies encapsulated in an 
extracellular matrix (ECM) of polysaccharides of Pseudomonas aeruginosa in lung tissue of 
cystic fibrosis patients [13]. Also, bacterial structures of Staphylococcus aureus attached to 
medical implants were discovered microscopically [14]. These studies provide the foundation of 
a branch of bacteriology that focuses on cells grown as a citizen of a sessile community rather 
than separated individuals. Biofilms consist of many cells aggregated into a highly structured 
community enclosed in ECM that contains fluid channels and even multiple bacterial species 
[15, 16]. 
Biofilm growth and development follows several specific stages. First, bacterial cells 
attach to a substratum. This is followed by non-motile, sessile growth and maturation of the 
biofilm through formation of architecture and ECM leading to stress gradients and phenotypic 
diversity. Finally, cells use quorum sensing and begin to disperse from the biofilm, to perhaps 
attach elsewhere and begin the process anew. Biofilm formation occurs through distinct genetic 
reprogramming of bacteria that occurs immediately after the attachment of a planktonic cell onto 
a substratum [17, 18]. In Escherichia coli for example, motility genes are suppressed by 
transcriptional regulation and up-regulating genes that produce components of the ECM [19]. 
Quorum sensing genes, a form of bacterial intercellular communication, were highly activated 
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while virulence genes were suppressed in biofilms of Vibrio cholera [20]. In Bacillus subtilis, a 
Gram-positive bacterium, another inverse correlation in gene regulation is observed during 
biofilm development. Regulators of ECM SinR and SinI negatively and positively regulate these 
genes respectively, while activation of sporulation genes negatively regulate biofilm formation 
by preventing sessile growth [21]. These data from gene expression and transcriptomic studies 
illustrates how bacteria forming biofilms and their distinct growth programs could give rise to 
heterogeneity in biofilms. These microenvironments present in separate portions of the 
architecture of the biofilm create phenotypic diversity across these subpopulations that is more 
tolerant to stress or antibiotic treatment. 
1.5 BIOFILMS AS A METHOD OF ANTIBIOTIC TOLERANCE 
As mentioned above, P. aeruginosa and S. aureus, two pathogenic bacteria, readily form 
biofilms in clinical settings. Pathogenic E. coli also form biofilms during infections of the 
urinary tract [22]. Across species, biofilms of pathogenic bacteria have proven to be both tolerant 
of antibiotic treatment as well as evasion of clearance by the host immune system [23, 24]. This 
makes effective treatment of bacterial infections caused by biofilm-forming bacteria a difficult 
prospect. Staphylococci species are 20-50 times more susceptible to antibiotic treatment in 
planktonic culture compared to biofilms [25]. This factor increases to planktonic cells being 100-
1000 times more susceptible than biofilm samples in pathogenic E. coli and P. auruginosa [26]. 
This leads to a more aggressive antibiotic treatment of biofilm infections or coating medical 
implants with antimicrobial substances, although there remains an absence of treatment for 
dispersing bacteria from a biofilm prior to antibiotic treatment [27]. A recent study identified the 
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D-amino acids as a potent dispersal agent of pathogenic biofilms, although this is yet to be tested 
clinically or with other antibiotics [28].  
1.6 POSSIBILITY OF CLINICAL MTB BIOFILMS 
As mentioned above, mycobacteria will naturally form multicellular communities in culture. 
Biofilms of mycobacteria have been observed in both the environment and with pathogenic 
species in clinical settings [29, 30]. Environmental species of mycobacteria have been observed 
in showerheads as well as water supply systems [31, 32]. This is especially true in the case of the 
opportunistic pathogen species M. avium. In the model non-pathogenic, fast-growing and non-
pathogenic model species M. smegmatis, it has been shown that during in vitro biofilm 
development glycopeptidolipids (GPL) are required for attachment and sliding motility [33]. 
Two other surface components necessary for biofilm development in M. smegmatis are free 
mycolic acids and mycolyl-diacylglycerol [34, 35]. Mycolyl-diacylglycerol is suspected to be 
key in the early attachment phase of biofilm development. This suggests cellular lipids play an 
important role in biofilm development in mycobacteria. A nucleoid-associated protein and 
suspected transcription regulator, lsr2, contributes to mycolic acid synthesis and biofilm 
development [36]. A regulator of genes involved in ECM synthesis would be in line with the 
distinct genetic expression profiles seen during biofilm development in other species of bacteria. 
Similar results of control of biofilm development at the transcriptional level is further 
demonstrated by the induction of 82 genes during biofilm maturation in M. smegmatis [37]. 
Growth of MTB in vitro without Tween-80 also leads to development of mature biofilm 
structures rich in free mycolic acid content [34]. Three genes, pks16, pks1 and helY have been 
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linked to biofilm development in MTB by the failure of their mutants to form mature biofilms, 
yet grow normally in planktonic culture [34, 38]. Biofilms of MTB and M. smegmatis grown in 
vitro also harbor populations of drug-tolerant cells compared to biofilm-deficient mutants or 
planktonic cultures. These findings support the distinct and multi-phasic growth pattern of 
biofilms in other species of bacteria also occur in mycobacteria. Also, in vitro, MTB has proven 
to be highly tolerant to antibiotic treatment much like other pathogenic bacteria that form 
biofilms clinically.  These results set the stage for the exploration of whether or not clinical 
biofilms of MTB could harbor a reservoir of drug-tolerant persisters in chronic and latent 
infections. 
1.7 USING TRANSPOSON JUNCTION SEQUENCING AS A METHOD OF 
DISCOVERING GENES CONTRIBUTING TO RIFAMPICIN TOLERANCE 
MTB has typically not been considered a very genetically tractable organism, however since the 
late 1990’s transposon insertion mutagenesis has proven to be a useful tool in elucidating a 
comprehensive view of genetic requirements for growth [39]. This approach was largely 
developed by Eric Rubin and Chris Sassetti. A highly active mariner transposon-based 
bacteriophage, ΦMycoMarT7, inserts itself into genomic DNA randomly at any “TA” site in the 
sequence. There are 74,417 of these sites in MTB (Erdman). This is used to create a large pool of 
mutants in colonies that can be harvested and stored in freezer stocks as a mutant library. This 
mutant library is then grown under a given growth condition.  Bacteria from each condition are 
then plated on media and colonies are harvested for DNA extraction. Junction sites of transposon 
insertion with genomic DNA are amplified by PCR using a primer with transposon homology 
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(see Methods below). Originally, this approach used microarray hybridization and was known as 
TraSH for transposon site hybridization [40]. More recently, next generation DNA sequencing of 
the amplified transposon junction sites in conjunction with mapping to a reference genome has 
become more commonly utilized (called Tn-Seq) [41]. This method has been used to identify 
genes in MTB essential for in vitro growth, growth in mice and macrophages and cholesterol 
catabolism. Here, we utilize this approach in the context of in vitro MTB biofilms when exposed 
to the frontline antibiotic rifampicin.  
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2.0  SPECIFIC AIMS 
 
In the context of the biofilm, bacteria at different levels of the structure express different levels 
of stress. For example, those at the surface with freer access to oxygen and nutrients will 
experience considerably less stress than the bacteria attached to the substratum at the bottom of 
the biofilm. The response to this stress, at the genetic level, could be the source of the phenotypic 
persistence to antibiotics observed during biofilm growth. By making a transposon mutant 
library of MTB, growing it in biofilms (as well as comparing it to planktonically grown 
samples), exposing the bacteria to rifampicin and sequencing colony DNA at transposon junction 
sites, our aim is to elucidate genetic factors that contribute to rifampicin tolerance in the context 
of a multicellular community of MTB. Our approach involves negative selection of non-essential 
genes by looking for insertion sites that are not represented or underrepresented in the mutant 
library for the rifampicin-treated samples as compared to the untreated samples (Figure 1). 
We predict that biofilms of the MTB mutant library challenged with brief exposure to 
rifampicin will identify genes which are most important for rifampicin-tolerance through their 
loss of representation in the sequencing data after exposure to the antibiotic. A decrease in the 
number of reads in the 24-hour, rifampicin-exposed samples at genomic sites where read 
numbers were high in the unexposed samples will be genes targeted in future studies for 
contributing to fitness and rifampicin tolerance in biofilms. 
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Figure 1. Demonstration of the determination of genes related to rifampicin tolerance by negative 
selection. 
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3.0  METHODS 
3.1 A SIMPLIFIED BIOFILM MODEL 
To begin to study the behavior of MTB within the context of a natural biofilm, a model was 
developed to grow the bacteria after attachment to a substratum and yet still be easily 
manipulated and handled for purposes of experimentation. This was done by first growing a 
culture of MTB (Erdman strain) in Middlebrook 7H9 media, Oleic Acid, Albumin, Dextrose 
Complex (OADC) and tween80 to an Optical Density (OD) at 600nm of 0.8-1.0 and then 
pipetting 10µl from the bacterial culture onto a 13mm in diameter polycarbonate membrane 
placed on top of a stack of cardstock strips inside of a Petri dish. After inoculation, membranes 
were allowed to dry for 45-60 minutes. 25ml of 7H9 and OADC were added to the Petri dish and 
absorbed by the cardstock up to the membranes through capillary action. The biofilm cultures 
were then incubated at 37ºC while the bacteria grew into mature biofilms for 18 days. Growth 
media was replenished as needed. Biofilms were processed by placing them into 15ml conical 
tubes containing 5ml of 1xPBS followed by mixing by vortex, sonication, a second vortexing 
and plating (Figure 2). All sonication (with the exception of the sonicator used for DNA 
shearing) was performed for ten minutes at 25ºC on the Branson 1510 model. 
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 Figure 2. Flow chart of membrane-attached biofilm model. 
3.2 TESTING DRUG TOLERANCE IN BIOFILMS 
To test drug tolerance of the MTB (Erdman) in biofilms, mature biofilms were grown as 
described above and then exposed to 5µg/ml of rifampicin for a period of 6 days. Biofilms were 
exposed to rifampicin by moving the top cardstock with the membranes to a new Petri dish 
containing a fresh stack of cardstock and 5µg/ml rifampicin in 25ml of 1xPBS. Unexposed 
biofilms were transferred to cardstock in a Petri dish containing 25ml of only 1xPBS. Following 
exposure, membranes were removed from the cardstock and placed into a 15ml conical tube 
containing 5ml of 1xPBS.  The tubes were vortexed until visible bacteria were dislodged from 
the membrane, and then tubes were sonicated for 10 minutes. After sonication, the membranes 
were vortexed for another two minutes. The bacteria from the membranes were then centrifuged 
for 10 minutes at 3488xg and 22ºC to wash any antibiotic off of the cells. Supernatant was 
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discarded, 5ml of fresh 1xPBS was added to the tubes, and the bacteria were re-suspended. At 
this point, the OD600 of the samples was measured. Serial dilutions were made and 10µl were 
pipetted at several dilutions onto 7H11 agar plates containing OADC plates for colony counts. 
For comparative analysis, planktonic samples of MTB were grown to an equal OD600 of the 
processed biofilm samples (described above) in 7H9 and OADC and subsequently underwent 
identical treatment as the biofilm samples for 5µg/ml rifampicin in 1xPBS exposure, vortexing, 
sonication, additional vortexing, centrifugation, washing and re-suspension in 1xPBS. The 
planktonic samples were diluted identically to the biofilm samples, and 10µl were pipetted onto 
7H11 and OADC plates for colony counts. 
3.3 TESTING RIFAMPICIN TOLERANCE OF BIOFILMS OVER 24 HOURS  
To acquire a timeframe of rifampicin exposure of mutants that would only see the weakest 
mutants die off from antibiotic killing, the above protocol was followed for biofilm samples of 
MTB (Erdman) and MTB mc27000 (an attenuated strain), but with 5µg/ml of rifampicin 
exposure only lasting 24 hours before biofilm processing and subsequent plating for counting 
colonies and calculating percent survival. 
3.4 CONSTRUCTION OF THE TRANSPOSON MUTANT LIBRARY 
A planktonic culture of MTB (Erdman) was grown in 7H9, OADC and tween80 to an OD600 of 
1.0. This culture was then sub-cultured into ten bottles containing 1ml from the original culture 
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grown in 25ml of 7H9, OADC and tween80 to OD600 0.8-1.0. The MTB stocks were then split 
into two sets of four 50ml conical tubes containing approximately 30ml each. The 50ml conical 
tubes were centrifuged at 2348xg for 5 minutes at 22ºC. Supernatant was removed and the pellet 
was washed and re-suspended in 20ml 1xPBS.  The bacteria were centrifuged again under the 
same conditions and re-suspended in 5ml of warm 7H9 and OADC. The cultures were then each 
infected with 1ml of the temperature sensitive ΦMycoMarT7 mycobacteriophage with a titer of 
1011 and incubated for four hours at 37ºC. The phage contains a himar1 mariner-based 
transposon that can insert into any “TA” site into the MTB genome. After incubation, each of the 
phage-transduced cultures were plated with one ml from each culture (5 plates from each tube, 
totaling 40 plates) on 15cm plates containing Middlebrook 7H11 agar containing OADC, 
tween80 with 20µg/ml of Kanamycin and incubated at 37ºC for 21 days. Approximately 12,000 
colonies of the transduced MTB were collected by pipetting a 2 to 5 milliliters of 7H9 and 
tween80 onto the 15cm 7H11, OADC, tween80 and Kanamycin plates and scraping the colonies 
off into the media [42]. From this, glycerol stocks of the mutant library were collected to be 
grown in culture. 
3.5 GROWTH CONDITIONS AND RIFAMPICIN EXPOSURE OF THE MUTANT 
LIBRARY 
The MTB transposon mutant library was grown in 7H9, OADC and Kanamycin to an OD600 of 
0.8-1.0. From there, the culture was either split into a new planktonic culture or 10µl were 
inoculated onto polycarbonate membrane for biofilm growth as stated above. Planktonic samples 
were grown to an OD600 of 0.8-1.0 and exposed to 5µg/ml rifampicin for 24 hours or left 
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unexposed to antibiotic, processed as stated above, plated on 15cm 7H11, OADC tween80 and 
Kanamycin and incubated for 21 days at 37ºC. Biofilm samples were grown to maturity at 18 
days, and then samples were exposed to 5µg/ml rifampicin for 24 hours or left unexposed to 
antibiotic and processed as stated above. After processing, cells from the biofilm samples were 
plated on 15cm 7H11, OADC, tween80 and Kanamycin and incubated at 37ºC for 21 days. 
3.6 EXTRACTION OF MUTANT GENOMIC DNA 
Colonies were harvested from the 15cm plates by pipetting 2 to 5 milliliters of 7H9 and tween80 
onto the plates, then scraping off colonies and collecting them into the 7H9 and tween80 media 
[42]. The colonies and media were centrifuged at 2348xg for 10 minutes at 22ºC. The 
supernatant was discarded and the pellet was re-suspended in 5ml 10mM Tris-HCl, 1 mM EDTA 
at a pH of 9. The re-suspended cells were mixed with an equal volume of chloroform and 
methanol in 2:1 ratio and rocked for 5 minutes on a shaker. The suspension was centrifuged at 
3488xg for 10 minutes at 22ºC. Both the aqueous and the organic phases were removed from the 
50mL conical tube. The solid bacterial mass was dried by leaving the tube open in the biosafety 
cabinet for 3 hours. Ten milliliters of TE containing 0.1M Tris-HCl at a pH of 9 was added to the 
pellet. The bacteria were then re-suspended by vortexing. A one hundredth volume of 10mg/ml 
lysozyme was added, and the cells were incubated overnight at 37ºC. One milliliter of 10% 
Sodium dodecyl sulfate (SDS) solution was added to the incubated cells. Proteinase K was added 
to the cells to a final concentration of 100g/mL and mixed via vortexing. The samples were 
incubated at 50ºC for 3 hours. The viscous solution was transferred into a clean tube containing 
an equal volume of phenol and chloroform in an equal 1:1 ratio. After mixing, the cells were left 
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to stand for 30 minutes. Then, the cells were rocked on a shaker for 30 minutes at, followed by 
centrifugation at 12000xg for 15 minutes at 22ºC. The upper aqueous phase was pipetted off to a 
new tube with an equal volume of chloroform and the centrifugation was repeated. Again, the 
upper aqueous phase was removed and pipetted into a new tube with an equal volume of 
isopropanol and a one tenth volume of 3M sodium acetate at a pH of 5.2. The DNA was spooled 
out and washed with 70% ethanol, and dissolved in 0.5 to 1 mL TE. 
3.7 PREPARATION OF DNA LIBRARY FOR HI-SEQ 2500 
DNA from untreated planktonic cultures, untreated biofilm cultures and biofilm cultures exposed 
to rifampicin for 24 hours were prepared for DNA sequencing. The genomic library preparation 
was adapted from a protocol used for transposon site sequencing by the Sassetti Laboratory at 
the University of Massachusetts [40]. The entire process of preparing the DNA library from 
shearing to amplification is depicted at the sequence level (Figure 3). To prepare the extracted 
genomic DNA from the transposon mutant library for sequencing at the transposon junction site, 
the DNA first had to be sheared into segments ranging 400-600 base pairs in length. This was 
done on a Covaris S2 Focused-ultrasonicator at the University of Pittsburgh Genomics and 
Proteomics Core Laboratories. To obtain the target base pair peak of 500bp, 130µl of each 
genomic DNA sample was placed in the sonicator set to an intensity of 3, 5% duty cycle, 200 
cycles per burst for 90 seconds at 7ºC with a water level of 12. The DNA was then run on a 1% 
agarose gel for 60 minutes at 100 volts, then the 400-600bp range of the smear was excised, gel 
extracted and column purified using Qiagen Gel Extraction kit to the manufacturer’s instructions. 
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 Figure 3. Preparation of DNA library for sequencing. 
The sheared DNA was blunt ended using Epicentre’s End-It DNA end repair kit 
according to the manufacturer’s instructions. An adenosine nucleotide was added to the 3’ end of 
each strand of blunt ended DNA by adding 5µl of Invitrogen 10x PCR buffer, 10µl of 100mM 
dATP and 3µl of Invitrogen Taq polymerase to each DNA sample and then incubating at 72ºC 
for 45 minutes. The DNA was then purified by using the Qiagen enzyme reaction clean up kit 
following the manufacturer’s instructions and eluted into 50µl of distilled water after column 
purification.  
To allow adapters to hybridize and prepare them for ligation to the genomic DNA 
fragments, 48µl from a 100µM stock of each adapter and 4µl of 50mM MgCl2 were mixed into a 
microcentrifuge tube and heated in a 95ºC water bath for ten minutes and were then cooled to 
room temperature.  The adapter sequences were 5’-TACCACGACCA-NH2-3’ and 5’-
ATGATGGCCGGTGGATTTGTGTGGTCGTGGTAT-3’. For each ligation reaction, 1µl DNA 
ligase, 1.5µl DNA ligase buffer and 1µl of the hybridized adapter mix were added to 11.5µl of 
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the A-tailed DNA samples and incubated at room temperature for an hour. Then, the reaction 
was spiked with 1µl DNA ligase, 1µl DNA ligase buffer and 8µl water and incubated at room 
temperature for two more hours. The Qiagen enzyme reaction clean up kit was used as per the 
manufacturer’s instructions with 3 additional washes of the DNA with PE buffer before elution 
into 100µl of water.  
Next, genomic DNA fragments were amplified to enrich transposon junction sites by 
PCR amplification using a primer with transposon homology (5’-
TAATACGACTCACTATAGGGTCTAGAG-3’) and a primer with homology to the adapter 
sequence (5’-ATGATGGGCCGGTGGATTTGTG-3’). The reaction mix for the PCR was 100ng 
of DNA, 5µl of 10x PCR buffer, 1.5µl 50mM MgCl2, 2.5µl of 5mM dNTPs, 2.5µl DMSO, 0.5µl 
Taq polymerase and 1.5µl of each primer from a 10µM stock. Water was added to each reaction 
to bring it up to a volume of 42µl. PCR parameters were 95ºC for 10 minutes; 20 cycles of 95ºC 
for 30 seconds, 58ºC for 30 seconds and 72ºC for 45 seconds; and 72ºC for 5 minutes. The 
amplified DNA was visualized on a 2% agarose gel run at 60 volts for 140 minutes. Smears of 
amplified DNA in the 400-600bp range were excised, placed in the negative 20ºC freezer for 30 
minutes and then gel extracted with the Qiagen Gel Extraction kit and eluted into 50µl of water. 
A quality control PCR was also run on first PCR product using the same parameters with a 
primer with transposon homology downstream of the original primer (5’-
GACTTATCAGCCAACCTGTTA-3’) and the same adapter primer as the first round. 
The last process in library preparation was further amplification of transposon junction 
site DNA with staggered primers with homology to the Illumina Tru-Seq adapter as well as 
transposon homology (Table 1) and primers with Illumina Tru-Seq adapter homology, a six-base 
long Illumina Index bar code for multiplexing and homology to the original adapters (Table 2).  
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 Table 1. Staggered PCR primers with Transposon and Illumina Tru-Seq adapter homology used in 
hemi-nested PCR for sequencing preparation. 
 Primer Sequences 
1 5’AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCG
ATCTCGGGGACTTATCAGCCAACC 3’ 
2 5’AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCG
ATCTTCGGGGACTTATCAGCCAACC 3’ 
3 5’AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCG
ATCTGATACGGGGACTTATCAGCCAACC 3’ 
4 5’AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCG
ATCTATCTACGGGGACTTATCAGCCAACC 3’ 
 
Table 2. Primers with adapter homology and Illumina barcode sequence for multiplexing 
 Sample Primer Sequences Barcode Sequence 
1 Untreated 
planktonic 
5’CAAGCAGAAGACGGCATACGAGATATCACGGTG
ACTGGAGTTCAGACGTGTGCTCTTCCGATCTGTCA
ATGATGGCCGGTGGATTTGTG 3’ 
CGTGAT 
2 Untreated 
biofilm 1 
5’CAAGCAGAAGACGGCATACGAGATCGATGTGTG
ACTGGAGTTCAGACGTGTGCTCTTCCGATCTGTCA
ATGATGGCCGGTGGATTTGTG 3’ 
ACATCG 
3 Untreated 
biofilm 2 
5’CAAGCAGAAGACGGCATACGAGATTTAGGCGTG
ACTGGAGTTCAGACGTGTGCTCTTCCGATCTGTCA
ATGATGGCCGGTGGATTTGTG 3’ 
GCCTAA 
4 24 hour 
RIF 
exposure 1 
5’CAAGCAGAAGACGGCATACGAGATTAGCTTGTG
ACTGGAGTTCAGACGTGTGCTCTTCCGATCTGTCA
ATGATGGCCGGTGGATTTGTG 3’ 
AAGCTA 
5 24 hour 
RIF 
exposure 1 
5’CAAGCAGAAGACGGCATACGAGATGGCTACGTG
ACTGGAGTTCAGACGTGTGCTCTTCCGATCTGTCA
ATGATGGCCGGTGGATTTGTG 3’ 
GTAGCC 
6 24 hour 
RIF 
exposure 1 
5’CAAGCAGAAGACGGCATACGAGATCTTGTAGTG
ACTGGAGTTCAGACGTGTGCTCTTCCGATCTGTCA
ATGATGGCCGGTGGATTTGTG 3’ 
TACAAG 
 
The staggered primers were mixed together in equal concentration prior to being added to the 
PCR mix. The reaction mix for hemi-nested PCR included 6µl of amplified DNA product from 
the first round of PCR, 2µl of 10x PCR buffer, 0.5µl of 50mM MgCl2, 0.5µl of dNTPs, 0.2µl Taq 
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polymerase, 0.2µl of the staggered transposon primer mix, 0.2µl of the adapter barcoded primer 
and 10.4µl of water for a final reaction volume of 20µl. PCR parameters were 95ºC for 5 
minutes; 10 cycles of 95ºC for 30 seconds, 58ºC for 30 seconds and 72ºC for 45 seconds; and 
72ºC for 5 minutes. Amplified DNA was run on a 1% agarose gel at 90 volts for 60 minutes. The 
400-600bp smear was excised and extracted using the Qiagen Gel Extraction kit as per the 
manufacturer’s instructions. 
3.8 ILLUMINA HI-SEQ 2500 DNA SEQUENCING 
After PCR amplification of transposon junction sites, 20ng of each sample of prepared DNA at a 
volume of 20nM was sent to Tufts University Core Facilities for Illumina Hi-Seq 2500 DNA 
sequencing [43]. The universal Illumina sequencing primer (5’- 
ACACTCTTTCCCTACACGACGCTCTTCCGATCT-3’) was used for single-end sequencing of 
the samples from the transposon end.  
The single stranded DNA fragments bind randomly to the surface of the flow cell 
channel, then added nucleotides facilitate bridge amplification of the input prepared DNA into 
double-stranded amplified fragments on the solid flow cell surface. The DNA is denatured again 
leaving a template for complete amplification of up to 40 million clusters of DNA per flow cell. 
Then, the actual sequencing process begins with four labeled reversible terminators, the 
sequencing primer, the index primer and DNA polymerase. The sequencing primer binds to the 
indexed adapter and fluorescently-labeled bases are added individually and the result is recorded 
by a camera. The index primer has adapter homology up to the six-base bar code sequence, 
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which is then read by the machine to differentiate between the individuals samples present in the 
multiplex. Ideally, this process can yield up to 200 million reads. 
3.9 ANALYSIS OF SEQUENCING DATA 
A combination of small perl-based computer programs, the open-source, browser-based Galaxy 
project bioinformatics tool and the Broad Institute’s Integrated Genome Viewer were used to 
analyze the results of DNA sequencing [44-46]. A small computer script provided by Dr. 
Richard Baker was used to check that the raw fastq files were checked to contain the “TGTTA” 
transposon junction site and then cleave off the beginning bases which contained transposon 
homology leaving the “TA” sequence where the transposon originally inserted itself into MTB’ 
genome during mutant library construction [41]. These processed fastq sequences were groomed 
using the Galaxy browser and quality statistics for the reads were calculated [47]. Also using 
Galaxy browser system, the fastq reads were mapped to the MTB (Erdman) genome using 
Bowtie [48] tool. Galaxy was then also used to convert mapped sam files to binary “bam” files 
for graphical viewing [49]. A second computer script was used to count the number of reads for 
each sample at each possible “TA” site across the entire genome. Mapped reads were viewed 
graphically along the genome in the Integrated Genome Viewer. Normalizations and 
differentiation of sequences were calculated using Microsoft Excel. 
 21 
3.10 QUANTITATIVE PCR AND ANALYSIS 
To attempt to confirm the presence of rifampicin-sensitive mutants observed from the 
sequencing data in the genomic DNA, quantitative PCR was performed on the DNA samples 
from the unexposed and rifampicin-exposed biofilms and planktonic cultures. A single 
transposon-based primer (5’-CGACTCACTATAGGGTCTAGAGAC-3’) was used as a forward 
primer in all reactions. The reverse primers for each individual gene, as well as two endogenous 
control sequences that had mapped insertions across all samples, had sequence homology with a 
downstream sequence of the gene after transposon insertion (Table 3). DNA input was 
normalized across samples by viewing genomic aliquots on a 1% agarose gel coupled with 
spectrophotometer readings. Each reaction contained 1µl DNA, 6.25µl SYBR Green Master 
Mix, 4µl water and 0.625µl of each primer for a final reaction volume of 12.5µl. 
 
Table 3. Reverse primers used in quantitative PCR for each gene 
Position of 
insertion 
Erdman 
gene # 
H37rv ortholog 
gene # 
Primer Sequences 
462570 E_0425 Rv0385 5’ GAGCTTAGAATCGAGGTCCG 3’ 
1691647 E_1681 Rv1508c 5’ CTTGCCCGATTGATAGTTCTTG 3’ 
2055036 E_2009 Rv1819c 5’ GGCGGTGAAGATATCGACG 3’ 
3073068 E_3045 Rv2779c 5’ GTCGGCATTGAGGTTTTCG 3’ 
3521539 E_3465 Rv3164c 5’ GGAGAGGTAGCGCAGTTC 3’ 
4231539 E_4162 Rv3796 5’ ACAGAGCGCCAAAGATGAG  3’ 
4324565 E_4241 Rv3868 5’ GGCTGTACGGCGATATCAC  3’ 
3072909   5’ GTGATCAGCCCGTATACCAG 3’ 
3787076   5’ GGCAAACCCGAATCAATGG 3’ 
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4.0  RESULTS 
4.1 THE PORTABLE BIOFILM MODEL AND DRUG-TOLERANT BACTERIA 
By growing MTB on a membrane, we were able to both manipulate the growth conditions of the 
bacteria, but also ensure that all bacteria were processed similarly, and all bacteria harvested 
were part of a biofilm population. In the past, our lab has assayed biofilms by using pellicles 
grown at the air-liquid interface [50], but this method often includes cells that are submerged in 
the liquid or settled at the bottom of the dish. The membrane-attached method allows for growth 
and manipulation of a biofilm attached to a solid substrate and processing of all the biofilms’ 
cells without accidental inclusion of suspended cells. 
Percent survival of cells grown in the membrane-attached biofilm method revealed 
biofilm cells to contain more persisters than their planktonic counterparts after exposure to the 
antibiotic rifampicin (Figure 4). MTB (Erdman) biofilms had a mean percent survival of 0.295% 
percent in the 18-day biofilms compared to 0.006% percent in the planktonic samples.  MTB is 
48 times more tolerant in biofilms than in planktonic culture. The student’s t-test calculation 
resulted in a test statistic of 3.31 for a p-value of <0.05, but slightly greater than 0.01 (a test 
statistic of 3.36 would result in a p-value of 0.01). Mean percent survival was calculated for 
planktonic (without tween-80) and 18-day biofilms of MTB after 6-day exposure to 5µg/ml 
rifampicin.  Bacteria concentration was normalized by measuring OD600 prior to plating.  Each 
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bar is the result of 3 independent experiments performed in triplicate with standard error bars 
showing range between samples. These experiments were performed in collaboration with a 
former post-doctoral fellow in the Ojha laboratory, Dr. Mohammad Islam. 
 
Figure 4. MTB mean percent survival to rifampicin in biofilm and planktonic culture. 
 
To obtain a clear picture of how long we could expose biofilms of MTB to 5µg/ml of 
rifampicin and only lose the most rifampicin-sensitive mutants from the population, 18-day 
biofilms of MTB (Erdman) and the attenuated mc27000 strain were exposed to 5µg/ml of 
rifampicin for a 24 hour period. This time period was revealed to kill off only a small percentage 
of the biofilm cells with a mean 88.57 percent survival in the mc27000 strain and 98.48 percent 
survival in the Erdman strain (Figure 5). The mean percent survival was calculated from three 
replicate experiments with standard error bars. This high percentage survival ensures that any 
loss of mutants through killing in the 24-hour exposure window represents the most rifampicin-
sensitive mutants in the library and not a loss from normal rifampicin treatment. 
 24 
 
 
Figure 5. Mean percent survival after 18-day biofilms were exposed to 5µg/ml rifampicin for a 24 
hour period. 
4.2 CONSTRUCTION OF THE MUTANT LIBRARY AND AMPLIFICATION OF 
TRANSPOSON JUNCTION SITES 
After infection with the ΦMycoMarT7 phasmid, up to 40 7H11, OADC, Kanamycin and twee80 
plates were incubated for 21 days resulting in a mutant library consisting of approximately 
12,000 colonies of clones carrying the transposon inserted into their DNA. This represents a 
limited, but still significant number of clones in the mutant library. The MTB (Erdman) genome 
has potentially 74,417 possible “TA” insertion sites, and an ideal library would consist of clones 
at least 2 to 3 times that number (the 200,000-300,000 range). The 12,000 clone library was used 
for the rifampicin-exposed biofilms and planktonic samples. 
The yield from genomic DNA extraction measured with a spectrophotometer varied from 
sample to sample as can be seen in the table below (Table 4). The measure of absorbance of 
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A260:A280 showed most samples still contained some protein contamination (A 100% nucleic 
acid preparation will have an A260:A280 of 1.8). Also, four of the samples had an A260:A230 
under 2.0, which is most likely the result of residual phenol in the ethanol precipitation. These 
contaminations were reduced upon subsequent column purification following the shearing of 
DNA for library preparation for sequencing. Because protein contamination contributes little to 
the absorbance, it is still unlikely that this affected the readings of the DNA concentrations by a 
spectrophotometer. 
 
Table 4. Genomic DNA concentrations and absorbance by nanodrop after extraction. 
Sample DNA concentration (ng/µl) A260:A280 A260:A230 
Planktonic 80 1.524 1.882 
0hr Biofilm 1 1000 1.802 2.116 
0hr Biofilm 2 205 1.708 1.783 
24hr Biofilm 1 205 1.745 2.000 
24hr Biofilm 2 85 1.360 1.308 
24hr Biofilm 3 335 1.558 1.861 
 
After DNA extraction, genomic DNA was sheared into fragments in the 400-600bp 
range. While the Covaris sonicator yielded a wide range of sheared DNA, it did successfully 
shear away all of the whole genomic DNA (as can be seen on the 1% agarose gel image) and 
only the DNA in the desired range was excised and gel extracted. (Figure 6). 
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Figure 6. Genomic DNA after shearing on a 1% agarose gel. 
 
In the gel image, lane 1 is a 100bp ladder, lanes 2 and 3 are from the unexposed planktonic 
sample, lanes (4 and 5) and (6 and 7) are from two separate unexposed biofilm samples. In the 
gel on the right, lanes (1 and2), (3 and 4) and (5 and 6) are each sheared DNA from 3 separate 
biofilm samples that were exposed to rifampicin for 24 hours and lane 7 is a 100bp ladder. After 
gel extraction, the sheared mutant library DNA from all samples was, blunt ended, A-tailed and 
Illumina adapters were ligated to the sheared fragments before PCR amplification of the 
transposon junction site in the DNA (See Methods). The first round of PCR used short primers to 
amplify transposon junction sites (Figure 7).   
 
Figure 7. First round of PCR with short primers. 
 1    2      3    4    5     6     7       
 
  1    2     3     4     5    6    7 
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In the gel image on the left, lane 1 is a 100bp ladder, lane 2 is the unexposed planktonic sample, 
lane 3 is the first unexposed biofilm sample, lane 4 is a failed and unused reaction and lane 5 is 
the second unexposed biofilm sample. In the gel image on the right, lane one is a 100bp ladder, 
lane 2 is the first 24-hour rifampicin-exposed sample, lane 3 is the second, and lane 4 is the third. 
DNA from this PCR reaction was excised, gel extracted, column purified and then the 2nd round 
of PCR was performed on the amplified product to yield amplified transposon junction sites 
flanked by sequences with homology to Illumina sequencing and index primers (Figure 8). This 
was the DNA sent to Tufts University Core Facility for Illumina Hi-Seq 2500. In the gel image 
on the left lane 1 is a 100bp ladder, lane 2 is a reaction with water instead of DNA, lane 3 is the 
unexposed planktonic sample, lane 4 is the first unexposed biofilm sample and lane 5 is the 
second unexposed biofilm sample. In the gel image on the right, lane 1 is a 100bp ladder, lane 2 
is a reaction with water rather the DNA, lanes 3, 4 and 5 are the first, second and third 24-hour 
rifampicin-exposed biofilm samples, respectively. 
 
Figure 8. Hemi-nested PCR with primers that have Illumina sequencing primer and indexing primer 
homology. 
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After preparation for sequencing, DNA concentration of the prepared fragments and 
absorbance were measured by nanospectrophotometer (Table 5). 
 
Table 5. DNA concentration and absorbance measured by nanodrop after library preparation for 
sequencing. 
Sample DNA concentration (ng/µl) A260:A280 A260:A230 
Planktonic 17.5 1.915 2.228 
0hr Biofilm 1 20.0 1.833 2.000 
0hr Biofilm 2 12.5 1.776 1.915 
24hr Biofilm 1 7.5 1.811 2.400 
24hr Biofilm 2 17.5 1.824 2.116 
24hr Biofilm 3 17.5 1.870 2.003 
 
4.3 DNA SEQUENCING REVEALS POTENTIAL MUTANTS SENSITIVE TO 
RIFAMPICIN TREATMENT 
The sequencing data returned from Tufts showed the number of reads ranging from 629,825 
reads for the second unexposed biofilm sample to 5,331,968 for third 24-hour rifampicin-
exposed biofilm sample. While this is not an overly large number of reads, the most rifampicin-
sensitive mutants may still be detected by testing only the mutants that show the largest 
differential in presence between the rifampicin-exposed and unexposed samples. The returned 
sequences did show high mean quality scores according to the fastqc report provided by Tufts for 
each sample and the mean quality score by base in each sequence (Table 6 and Figure 9). 
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Table 6. Basic statistics from DNA sequencing run. 
Sample # of Reads % of Raw 
Clusters 
per Lane 
% Perfect 
Index 
Reads 
% One 
Mismatch 
Reads 
(Index) 
%  of >= 
Q30 
Bases 
Mean 
Quality 
Score 
Planktonic 850,447 4.15 100.0 0.0 93.65 37.29 
0hr Biofilm-1 2,366,430 11.54 100.0 0.0 92.94 37.09 
0hr Biofilm-2 629,825 3.07 100.0 0.0 93.74 37.27 
24hr Biofilm-1 2,859,380 13.95 100.0 0.0 93.06 37.11 
24hr Biofilm-2 2,397,451 11.69 100.0 0.0 93.55 37.22 
24hr Biofilm-3 4,172,700 26.00 100.0 0.0 93.37 37.17 
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 Figure 9. Quality scores across all bases for each sample. Top left: planktonic, top right: 0hr Biofilm-
1, Middle left: 0hr Biofilm-2, Middle right: 24hr Biofilm-1, Bottom left: 24hr Biofilm-2, Bottom right: 24hr 
Biofilm-3. 
  
After processing the raw fastq files and mapping with Bowtie to the MTB (Erdman) genome, 
roughly two-thirds of the returned reads aligned to a TA site. The exact values for each sample 
are set out in the table below (Table 7). The number of specific “TA” sites that had insertions 
mapped to them ranged from 12,265 for the planktonic sample and 22,720 for the third 24-hour 
rifampicin-exposed sample.  
Table 7. Results for the number of reads mapped to TA sites for each sample. 
Sample 
Name 
Total Reads Reads 
processed 
Reads 
discarded 
Insertions 
mapped to 
top strand 
Insertions 
mapped to 
bottom 
strand 
Unaligned 
reads 
Mismatched 
at TA reads 
Total TA 
sites hit 
Planktonic 850447 667528 182919 286169 278750 102224 385 12265 
0hr exp. 1 2366430 1810105 556325 800679 788436 219993 997 20976 
0hr exp. 2 629825 497303 132522 226720 237319 33013 251 12526 
24hr exp. 1 2859380 2237301 622079 1023866 1005918 206552 965 20287 
24hr exp. 2 2397451 1885675 511776 876007 857451 151646 571 19295 
24hr exp. 3 5331968 4181889 1150079 1935076 1897399 347300 2114 22720 
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 The first unexposed biofilm sample (0hr exp. 1), had the most aligned reads among the 
unexposed (therefore being the most representative), and was hence used as the reference 
sample. Reads for each insertion in the other samples were normalized to the number of reads 
from this reference sample. Eight insertion sites that were located inside of seven different open 
reading frames (E_1681 had two insertion points which showed great differentiation between the 
exposed and unexposed samples) were selected for having insertion mutants highly present in the 
unexposed samples but much less so in rifampicin-exposed samples. Other TA sites either had 
too little insertions (<100) to determine a meaningful difference or insertion counts were even 
across exposed and unexposed samples or were too varied among the exposed and unexposed 
classes.  
The eight genomic positions and their respective Erdman gene numbers are: 462570 at 
E0425, 1691647 and 1691886 at E1681, 2055036 at E2009, 3073036 at E3045, 3521539 at 
E3465, 4231539 at E4162 and 4324565 at E4241. These sites had insertions on both strands of 
the genome, but were especially diminished in samples exposed to 24 hours of rifampicin 
treatment. Alignments were visualized in Broad’s Integrated Genome Viewer (Figure 10 and 11 
are two examples captured by screenshots). Figure 10 shows a zoomed out screenshot of 
alignments mapped to E1681-E1689 (each gray marker is an individual alignment). Figure 11 
shows this area zoomed in to E1681 with each gray bar showing alignments to specific points in 
the genome. Mismatched nucleotides are shown in color inside the gray area of an alignment. 
Note the multiple positions and orientations of alignments at this site. These images were taken 
from viewing the bam file showing the mapping of the 0hr Biofilm-1 sample (the unexposed 
reference). The number of insertions after normalization across all samples is displayed in the 
bar graph in Figure 12.  
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 Figure 10. Alignments of insertions sites in the 1,690 to 1,700kb area of the MTB (Erdman) genome 
in IGV. 
 
 
Figure 11. Alignments of insertions sites zoomed into 55bp window showing alignments in the 
unexposed biofilm sample to E1681. 
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Figure 12. Total insertions mapped to eight different genomic positions in unexposed and exposed 
DNA samples. 
 
A ratio was calculated of the difference between insertions present in the reference sample to the 
mean number of insertions across the three rifampicin-exposed samples (Figure 13). The error 
bars represent the standard deviation between the three exposed samples. Genomic positions 
have been labeled by their corresponding locus from the H37Rv strain of MTB. The gene names 
and functions for each gene (or proposed functions for poorly characterized genes) being 
investigated is also summarized (Table 8). Rv3796 had the highest differential between 
unexposed and the exposed samples at 9.94. The ratios in descending order are Rv3796: 9.94, 
Rv2779c: 6.90, Rv1508c (position 2): 5.15, Rv1819c: 4.79, Rv3868: 4.73, Rv3164c: 4.24, 
Rv1508c (position 1): 3.67 and Rv0385: 2.66. These seven genes comprise the group with the 
greatest difference in insertions between unexposed and exposed samples. 
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 Figure 13. Ratio of number of insertions in the unexposed reference sample to mean of the 
rifampicin-exposed samples. 
 
Table 8. Proposed genetic factors that contribute to rifampicin tolerance and their functions. 
Genome 
position 
Erdman 
gene # 
Similar 
H37rv# 
Gene Name/Proposed Function 
462570 E0425 Rv0385 probable monooxygenase 
1691647 E1681 Rv1508c probable membrane protein of glycosyltransferase family 
1691886 E1681 Rv1508c probable membrane protein of glycosyltransferase family 
2055036 E2009 Rv1819c drug-transport transmembrane ATP-binding protein ABC 
transporter 
3073068 E3045 Rv2779c LRP/AsnC family transcriptional regulator 
3521539 E3465 Rv3164c moxR3 - methanol dehydrogenase transcriptional regulatory 
protein 
4231539 E4162 Rv3796 putative arylsulfatase 
4324565 E4241 Rv3868 AAA ATPase (ESX conserved component EccA1. ESX-1 
type VII secretion system protein) 
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4.4 CONFIRMATION OF MUTANTS USING QUANTITATIVE PCR 
Despite several attempts to confirm a differential representation in mutants by quantitative PCR, 
we were unable to accurately measure the presence of insertions across samples involved in the 
experiment. Even in the case of the insertion sites chosen for endogenous controls which 
represented similar insertion numbers across samples in both unexposed and exposed conditions, 
amplification in duplicate PCR runs did not return consistent CT values for even identical 
samples. It is possible that this is due to some inherent difficulty in measuring the level of 
transposon junction site DNA at a specific location among a pool of mutants. 
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5.0  DISCUSSION 
The results of the DNA sequencing identified seven genes that showed a high number of 
insertions at positions in their genes in the unexposed samples, but that were diminished in the 
rifampicin exposed samples. Transposon insertion mutagenesis has been a useful and reliable 
tool in demonstrating the essentiality of genes under certain growth conditions for the past 
twelve years. With the limited pool of mutants, only 22,720 of a possible 74,417 transposon 
mutants were examined, we were able to identify eight specific genomic positions that could 
contribute to rifampicin tolerance. To develop a more comprehensive view as to which genes 
contribute to rifampicin tolerance, the experiment will be repeated with more replicates in a 
denser library of mutants that can be guaranteed to represent all possible “TA” sites outside of 
genes essential for in vitro growth. It is possible that this could be achieved using the H37Rv 
MTB strain, which is more often used for genetic manipulation than the Erdman strain.  The 
more “TA” sites that have been disrupted by transposon insertion, the more representative the 
pool of mutants with dysfunctional genes will be. However, this project demonstrates the 
feasibility of the transposon mutant-based approach.  
Because of the relatively low concentration of and brief exposure time to antibiotic, it is 
plausible that these mutants are among the hyper sensitive clones to rifampicin clones. This is 
further supported by the fact that the biofilms of MTB (Erdman) wildtype when exposed to the 
same antibiotic treatment saw 98 percent survival of the bacteria. Overall, we believe these seven 
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mutants warrant further investigation and characterization in their roles in rifampicin tolerance 
and biofilm fitness.  
The gene identified to have the greatest differentiation between the unexposed reference  
sample and the biofilms exposed to rifampicin was E4162, corresponding to Rv3796. Rv3796 is 
a poorly characterized, non-essential hypothetical protein and putative arylsulfatase [51].  
Arylsulfatases are a class of enzymes that catalyze the hydrolysis of a phenol sulfate. The amino 
acid sequence of Rv3796 shows similar sequence with the metallo-beta-lactamase protein 
domain and twin arginine translocation (Tat) pathway signal sequence [52-54]. The metallo-beta-
lactamase protein domain is often a component of proteins involved in antibiotic resistance, 
while the Tat sequence is thought to play a role in transporting folded proteins across the lipid 
bilayer, and it has been suggested that phospholipase virulence factors in MTB are exported in a 
Tat-dependent manner [55-57]. Four genes in MTB encoding Phospholipases C were up-
regulated in the first 24 hours of macrophage infection and triple and quadruple mutants of these 
genes attenuated the bacteria in a mouse model [58]. This makes Rv3796 an intriguing gene to 
play a role in rifampicin tolerance in MTB as its amino acid sequence is linked to both the 
pathogen’s ability to breakdown antibiotic and to remain virulent. 
The genetic factor with the second-highest differential ratio was E3045, or its 
corresponding H37rv gene loci, Rv2779c. Rv2779c is a non-essential, DNA-binding protein and 
is most likely a transcriptional regulatory protein of the Lrp/AsnC family (leucine responsive 
regulatory protein/regulator of asparagine synthase C gene product) [51, 53]. Lrp/AsnC family 
regulators have been highly induced during nutrient starvation, a state relative to the biofilm 
model, and have been linked to persistence as well as the regulation of pili synthesis, amino acid 
metabolism and DNA repair and recombination [11, 59]. 
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E1681, or Rv1508c, had the third highest differential ratio, and the data showed high 
differential in the number of insertions in the unexposed to exposed samples at two genomic 
positions. The Rv1508c gene is a non-essential gene that codes for a hypothetical protein that has 
been proposed to be a membrane-bound glycosyltransferase [41, 53, 60]. A portion of the 
peptide this gene codes for has been previously proposed among a group of potential targets for 
diagnosis because of their MTB specificity and absence in Mycobacterium bovis BCG [61, 62]. 
The gene has also been noted to be possibly up-regulated in macrophage infection [63]. The 
cluster of biosynthetic genes in this region of the genome, including Rv1508c and known 
glycosyltransferases have been linked to synthesis of mycolic acids, which play an important role 
in the virulence of MTB  [64]. 
E2009, or Rv1819c, another gene identified by its rifampicin sensitive mutant, codes for 
bacA, a gene for a probable ATP-binding cassette transporter protein and has speculated to play 
a role in export of antibiotic export across the cellular membrane as an efflux pump making its 
possible involvement in rifampicin tolerance intuitive [65, 66]. The gene’s role was deduced by 
its sequence containing known ABC transport protein domains and further illustrated to be active 
during antibiotic challenge. Mice infected with this mutant showed tolerance to the cancer 
medication bleomycin and survived longer after infection [67]. ABC transporter’s role in 
antibiotic resistance has been well-documented in many bacteria including MTB [68, 69]. 
Rv1819c has been shown to be up-regulated during isoniazid exposure, but not rifampicin, and it 
along with seven other efflux pump genes have shown increased activity in MDR strains of the 
bacteria [70, 71]. It has also been implicated in the transport of lipids across the cellular 
membrane as it contains a lipid attachment site [72]. The gene is non-essential for growth [51]. 
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E4241, or Rv3868, is a gene encoding for an EccA1, an AAA ATPase (ATPases 
associated with diverse cellular activities) with conserved domains of a type VII secretion system 
[73]. These enzymes hydrolyze ATP to move macromolecular substrates across the cell wall. 
The type VII secretion system is unique to mycobacteria and is necessary for moving proteins 
across the generally impermeable mycobacterial cell wall. EccA1, while non-essential for in 
vitro growth, is required for growth in the mouse model or in primary macrophages making it 
difficult for further characterization [74-76]. MTB has several variants of type VII secretion 
systems and ATPase components, and EccA1 is one of two involved with transporting virulence 
factors outside of the cell [77, 78]. The EccA1 gene is required for the secretion of T-cell and B-
cell antigens ESAT-6 and CFP-10 [79].  This system has also been referred to as the ESX-1 
virulence factor secretion pathway. A deletion mutant of EccA1 in Mycobacterium marinum, an 
opportunistic pathogen, was shown to have decreased synthesis of mycolic acids, a core 
component of the mycobacterial cell wall [80]. 
Rv3164c, corresponding to E3465 was the sixth mutant identified in this study. This gene 
encodes the probable methanol dehydrogenase transcriptional regulator protein MoxR3 which is 
thought to regulate genes involved in methanol oxidation reactions. MoxR3 is non-essential for 
in vitro growth and like Rv3868 shows homology in sequence with proteins associated with 
AAA ATPases [51, 53, 65]. However, any link of this gene product to antibiotic tolerance 
remains unclear, although its role in the MTB regulatory network has been proposed [81]. 
 E0425, or Rv0385. Rv0385 encodes a probable monooxygenase enzyme protein based 
on its similarities in sequence to other monoxygenase genes at the C-terminus [53]. The gene is 
non-essential for in vitro growth [51]. Monooxygenase enzymes function by adding hydroxyl 
groups to their substrates in many metabolic pathways. Rv0385 also has approximately 25 
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percent sequence homology with flavohemoglobin proteins [82] and could act as a dioxygenase 
with nitric oxide as many bacterial flavohemoglobin proteins do [83]. Bacteria overexpressing 
this gene had an advantage in countering oxidative stress, and it has been suggested Rv0385 
allows MTB to balance oxidative stress levels and reduce damage to the cellular membrane [84]. 
This could provide a unique function to this protein in the biofilm context where many cells at 
the lower level of the structure are exposed to oxidative stress. It is possible that this stress 
management helps the bacteria persist in the presence of antibiotics like rifampicin. 
This study, still an initial assessment, provides a valuable proof of principal for the 
approach of using a transposon mutant library screen in MTB biofilms for examining rifampicin 
tolerance and fitness from a genomic perspective, and it has identified several genes for 
investigation that when disrupted by transposon insertion caused rifampicin sensitivity. It has 
generated several hypotheses as to the various mechanisms to this sensitivity for each gene. A 
full characterization of each mutant and the mechanism by which it contributes to rifampicin 
tolerance would provide powerful insight into the persistence of MTB as a pathogen. If possible, 
these gene products could be further targeted or exploited to compromise the persistence ability 
of MTB, thereby facilitating a shorter antibiotic intervention for tuberculosis. 
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6.0  FUTURE DIRECTIONS 
Moving forward from these findings, the next step is a characterization of the mutants identified 
and confirmed to be highly represented in the unexposed samples, but less so in the samples 
exposed to rifampicin. First, deletion or loss of function mutants for the genes observed in the 
sequencing data must be obtained followed by testing rifampicin sensitivity both planktonically 
and in the membrane-based portable biofilm model here. From there, these mutants will be 
studied in vitro in macrophages and in vivo in the mouse model for response to rifampicin 
treatment after infection with each rifampicin-sensitive mutant. The mutants could be tagged 
with fluorescent protein and mouse lungs could be processed and viewed under the microscope 
to characterize the locale of persistent infection and check for the presence of acellular biofilms 
in the mouse lung tissue. Beyond that, the next steps would be complementing the mutants to 
restore regular rifampicin tolerance and characterizing the mechanism by which the genes’ 
products confer rifampicin tolerance or sensitivity when knocked out. 
To further generate possible genes that contribute to rifampicin tolerance, we have 
already begun to replicate the same experiment in a much denser transposon mutant library in 
MTB mc27000 strain. This library was previously made by Anil Ojha and contains 
approximately 80,000 transposon mutants. The DNA from the cultures exposed to rifampicin 
will be prepared using the same protocol here sent off for sequencing and undergo the same 
protocol for data analysis, allowing us to generate hypotheses and quickly analyze results based 
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off of the sequencing data. A denser mutant library is also being prepared in the virulent MTB 
H37rv strain for repeat experiments.  This will provide the laboratory with a set of genes to 
explore the role and mode of rifampicin tolerance in not only MTB pathogenesis, but also the 
extent to which this tolerance is related to biofilm behavior and development in tuberculosis 
infection. It would also benefit to see if these genes each contribute to antibiotic tolerance for 
multiple drugs or if it is rifampicin-specific. Further down the pipeline, the products of these 
genes could be exploited in the treatment of persistent tuberculosis infection to potentially 
decrease the time required for pharmaceutical intervention, DOTS and eventually an overall 
decrease in the burden of disease.  
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